DeepMed Research

University Health Network

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1999-01-01

Employees: 10K

Market Cap: -

Website: http://www.uhn.ca

Clinical Trials

Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: cisplatin
Drug: erlotinib hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2018-10-10

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 51

Registration Number: NCT00030576

Locations: 🇨🇦
Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
Queen's University, Kingston, Ontario, Canada

and more 3 locations

Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: imatinib mesylate
Drug: irinotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 9

Registration Number: NCT00052494

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00045513

Locations: 🇨🇦
Princess Margaret Hospital at University Health Network, Toronto, Ontario, Canada
🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
London Health Sciences Centre, London, Ontario, Canada

Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00052507

Locations: 🇨🇦
Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada

and more 1 locations

Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Phase 2

Completed

Conditions: Liver Cancer

Interventions: Biological: oblimersen sodium
Drug: doxorubicin hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2017-11-08

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 27

Registration Number: NCT00047229

Locations: 🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: 7-hydroxystaurosporine
Drug: topotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2016-06-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 33

Registration Number: NCT00045175

Locations: 🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: imatinib mesylate

First Posted Date: 2003-01-27

Last Posted Date: 2019-02-15

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 16

Registration Number: NCT00045669

Locations: 🇺🇸
Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States
🇺🇸
LaGrange Memorial Hospital, LaGrange, Illinois, United States
🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States

and more 12 locations

Tipifarnib in Treating Patients With Recurrent Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00047216

Locations: 🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇨🇦
St. Joseph's Hospital, Hamilton, Ontario, Canada

and more 4 locations

Angioplasty and Heart Stents to Treat Individuals With an Occluded Artery Following a Heart Attack

Phase 4

Completed

Conditions: Coronary Disease
Heart Diseases
Myocardial Infarction
Cardiovascular Diseases

Interventions: Behavioral: Optimal Medical Therapy
Device: PCI with stenting

First Posted Date: 2001-10-23

Last Posted Date: 2013-11-27

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 380

Registration Number: NCT00025766

Locations: 🇨🇦
University Health Network - Toronto General Hospital, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy